Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.5 EUR | +0.61% | -1.20% | +96.43% |
06-10 | MorphoSys AG(XTRA:MOR) dropped from S&P Global BMI Index | CI |
06-06 | MorphoSys AG Announces Board Changes | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+96.43% | 2.72B | - | ||
+35.14% | 51.07B | B- | ||
-7.43% | 38.78B | B | ||
+35.88% | 38.61B | A | ||
-10.62% | 27.32B | C | ||
+11.63% | 26.35B | B- | ||
-17.77% | 19.46B | B | ||
+40.52% | 13.58B | B+ | ||
+30.70% | 12.46B | C+ | ||
-3.41% | 11.75B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MOR Stock
- MOR2 Stock
- Ratings MorphoSys AG